Details

Autor(en) / Beteiligte

• Wang, Weizhi
• Ma, Zhuoran
• Zhu, Shoujun
• Wan, Hao
• Yue, Jingying
• Ma, Huilong
• Ma, Rui
• Yang, Qinglai
• Wang, Zihua
• Li, Qian
• Qian, Yixia
• Yue, Chunyan
• Wang, Yuehua
• Fan, Linyang
• Zhong, Yeteng
• Zhou, Ying
• Gao, Hongpeng
• Ruan, Junshan
• Hu, Zhiyuan
• Liang, Yongye
• Dai, Hongjie

Titel

Molecular Cancer Imaging in the Second Near‐Infrared Window Using a Renal‐Excreted NIR‐II Fluorophore‐Peptide Probe

Ist Teil von

• Advanced materials (Weinheim), 2018-05, Vol.30 (22), p.e1800106-n/a

Ort / Verlag

Germany: Wiley Subscription Services, Inc

Erscheinungsjahr

2018

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• In vivo molecular imaging of tumors targeting a specific cancer cell marker is a promising strategy for cancer diagnosis and imaging guided surgery and therapy. While targeted imaging often relies on antibody‐modified probes, peptides can afford targeting probes with small sizes, high penetrating ability, and rapid excretion. Recently, in vivo fluorescence imaging in the second near‐infrared window (NIR‐II, 1000–1700 nm) shows promise in reaching sub‐centimeter depth with microscale resolution. Here, a novel peptide (named CP) conjugated NIR‐II fluorescent probe is reported for molecular tumor imaging targeting a tumor stem cell biomarker CD133. The click chemistry derived peptide‐dye (CP‐IRT dye) probe afforded efficient in vivo tumor targeting in mice with a high tumor‐to‐normal tissue signal ratio (T/NT > 8). Importantly, the CP‐IRT probes are rapidly renal excreted (≈87% excretion within 6 h), in stark contrast to accumulation in the liver for typical antibody‐dye probes. Further, with NIR‐II emitting CP‐IRT probes, urethra of mice can be imaged fluorescently for the first time noninvasively through intact tissue. The NIR‐II fluorescent, CD133 targeting imaging probes are potentially useful for human use in the clinic for cancer diagnosis and therapy. One novel peptide (CP)‐conjugated NIR‐II targeting fluorescent probe for molecular tumor imaging is developed toward a tumor stem cell receptor CD133. The peptide–dye probe shows efficient in vivo tumor targeting behaviors in mice with a high tumor‐to‐normal tissue signal ratio and can be renally excreted rapidly, in contrast to accumulation in the liver for typical protein–dye probes.